143 related articles for article (PubMed ID: 35835634)
1. An Update to the Malthus Model for Radiotherapy Utilisation in England.
Heritage S; Sundaram S; Kirkby NF; Kirkby KJ; Mee T; Jena R
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e1-e9. PubMed ID: 35835634
[TBL] [Abstract][Full Text] [Related]
2. Variations in Demand across England for the Magnetic Resonance-Linac Technology, Simulated Utilising Local-level Demographic and Cancer Data in the Malthus Project.
Mee T; Vickers AJ; Jena R; Kirkby KJ; Choudhury A; Kirkby NF
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e285-e294. PubMed ID: 33775495
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy demand and activity in England 2006-2020.
Round CE; Williams MV; Mee T; Kirkby NF; Cooper T; Hoskin P; Jena R
Clin Oncol (R Coll Radiol); 2013 Sep; 25(9):522-30. PubMed ID: 23768454
[TBL] [Abstract][Full Text] [Related]
4. Quantifying uncertainty in radiotherapy demand at the local and national level using the Malthus model.
Jena R; Mee T; Kirkby NF; Williams MV
Clin Oncol (R Coll Radiol); 2015 Feb; 27(2):92-8. PubMed ID: 25500188
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy in England in 2007: modelled demand and audited activity.
Williams MV; Drinkwater KJ
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):575-90. PubMed ID: 19651499
[TBL] [Abstract][Full Text] [Related]
6. The Malthus Programme: developing radiotherapy demand models for breast and prostate cancer at the local, regional and national level.
Round C; Mee T; Kirkby NF; Cooper T; Williams MV; Jena R
Clin Oncol (R Coll Radiol); 2013 Sep; 25(9):538-45. PubMed ID: 23791157
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Change in the Use of Fractionation in Radiotherapy Used for Early Breast Cancer at the Start of the COVID-19 Pandemic: A Population-Based Cohort Study of Older Women in England and Wales.
Gannon MR; Dodwell D; Miller K; Horgan K; Clements K; Medina J; Kunkler I; Cromwell DA
Clin Oncol (R Coll Radiol); 2022 Sep; 34(9):e400-e409. PubMed ID: 35691761
[TBL] [Abstract][Full Text] [Related]
9. Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic.
Faivre-Finn C; Fenwick JD; Franks KN; Harrow S; Hatton MQF; Hiley C; McAleese JJ; McDonald F; O'Hare J; Peedell C; Pope T; Powell C; Rulach R; Toy E
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):481-489. PubMed ID: 32405158
[TBL] [Abstract][Full Text] [Related]
10. Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation.
Williams MV; Drinkwater KJ
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):431-40. PubMed ID: 19560908
[TBL] [Abstract][Full Text] [Related]
11. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
12. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature.
Kong C; Guo WJ; Zha WW; Zhu XZ; Huang SF; Zhang YW; Xu JH; He X
Lung Cancer; 2014 Apr; 84(1):7-12. PubMed ID: 24548340
[TBL] [Abstract][Full Text] [Related]
13. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
15. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
Fornacon-Wood I; Banfill K; Ahmad S; Britten A; Carson C; Dorey N; Hatton M; Hiley C; Thippu Jayaprakash K; Jegannathen A; Kidd AC; Koh P; Panakis N; Peedell C; Peters A; Pope A; Powell C; Stilwell C; Thomas B; Toy E; Wicks K; Wood V; Yahya S; Price G; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e593-e600. PubMed ID: 37507280
[TBL] [Abstract][Full Text] [Related]
16. A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England.
Fulop NJ; Walton H; Crellin N; Georghiou T; Herlitz L; Litchfield I; Massou E; Sherlaw-Johnson C; Sidhu M; Tomini SM; Vindrola-Padros C; Ellins J; Morris S; Ng PL
Health Soc Care Deliv Res; 2023 Jul; 11(13):1-151. PubMed ID: 37800997
[TBL] [Abstract][Full Text] [Related]
17. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials.
Tabrizi S; Trippa L; Cagney D; Aizer AA; Tanguturi S; Ventz S; Fell G; Bellon JR; Mamon H; Nguyen PL; D'Amico AV; Haas-Kogan D; Alexander BM; Rahman R
JAMA Netw Open; 2021 Mar; 4(3):e213304. PubMed ID: 33779742
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D
BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135
[TBL] [Abstract][Full Text] [Related]
20. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
